Calypso deal with Japanese gastrointestinal specialist

31 March 2017

Calypso Biotech, a spin-off from German pharma major Merck KGaA (MRK: DE), has granted gastrointestinal specialist EA Pharma an exclusive and worldwide license for the development, manufacturing and marketing of CALY-001.

This anti-MMP-9 fully human monoclonal antibody is seen as a promising novel treatment for indications such as inflammatory bowel disease (IBD), potentially capable of preventing disease complications.

Both companies will collaborate to develop this candidate for IBD. Calypso Biotech will receive an undisclosed upfront sum as well as milestone and royalty payments from EA Pharma, which was inaugurated in April 2016 when Japanese pharma major Eisai (TYO: 4523) and food company Ajinomoto (TYO: 2802) combined their gastrointestinal pharmaceutical businesses into a new joint venture. The aim of the venture is to become Japan's largest gastrointestinal specialty pharma company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK